CTI BioPharma
SERVICES PROVIDED:
- Strategic Positioning
- Identity Design
- Campaign Development
- Website Design & Development
- Photography
- Social Media Channel Design
Design partner: Spirolab
CTI BioPharma is focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers. The company’s lead product, VONJO™, was approved by the FDA in February 2022.
In advance of the FDA decision on VONJO, 22 Fillmore worked with CTI on a corporate identity rebrand to get the company ready for its transition into being a commercial-stage company.
The scope of work consisted of the design of a new corporate logo and related identity system, the creation of a brand positioning campaign, and the development of a new corporate website.
The new “We Start With Them” creative platform emphasizes the company’s commitment to developing novel drugs to meet clearly defined patient needs and is featured on the homepage of the company’s completely redesigned website.
CTI BipPharma was acquired by Sobi in 2023.
